Bristol-Myers (BMY) -0.2% following its Q4 earnings miss, which was due to weaker-than-expected...

|About: Bristol-Myers Squibb Company (BMY)|By:, SA News Editor

Bristol-Myers (BMY) -0.2% following its Q4 earnings miss, which was due to weaker-than-expected sales of Plavix and higher costs. Revs were boosted by increasing sales of anti-infective drugs and a new skin-cancer treatment. Guidance: 2012 revs $17.2B-$18.2B vs. consensus of $18.3B and EPS $1.90-$2 vs. $1.96.